Clinical Trial Update: Immunological Response of Bladder Cancer Patients Under BCG [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the immunological response of bladder cancer patients treated with Bacillus Calmette-Guerin (BCG); the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guerin (BCG) (Bacillus Calmette-Guerin)

Snippet

Sponsor: University of Campinas, Brazil | Conditions: Bladder Cancer, Bacillus Calmette-Guerin | Phase 3 | Status: COMPLETED